The EPHA1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Raji B lymphoblast cell line, providing a heterogeneous pool of cells with disrupted EPHA1 expression. This loss-of-function model is intended for researchers studying ephrin receptor tyrosine kinase signaling without the need for single-cell cloning, offering a practical tool for functional and mechanistic investigations.
The parental Raji cell line is a well-characterized human B lymphocyte model derived from a Burkitt??s lymphoma patient. Raji cells are extensively used in immunology and cancer research due to their lymphoblast phenotype, expression of B-cell surface markers, and suitability for suspension culture. They serve as a robust system for examining signaling pathways that govern lymphocyte biology, tumorigenesis, and drug responses.
EPHA1 functions as a receptor tyrosine kinase that binds GPI-linked ephrin-A ligands (EFNA1?CEFNA5), initiating bidirectional signaling cascades. Upon ligand engagement, EPHA1 activates downstream effectors including SRC family kinases and focal adhesion kinase (FAK), which subsequently modulate Rho GTPases (RhoA, Rac1, Cdc42) to control cytoskeletal reorganization. This pathway integrates with PI3K-Akt and MAPK signaling, and it also impinges on integrin-mediated adhesion and migration. Adaptor proteins such as NCK1 and CRK facilitate the assembly of signaling complexes, linking receptor activation to cellular responses.
In Raji B lymphoblasts, EPHA1 may play a role in regulating adhesion, migration, and interactions within the tumor microenvironment. Disruption of EPHA1 signaling can potentially alter the intrinsic properties of Burkitt??s lymphoma cells, affecting their trafficking, homing, or response to extrinsic cues. This polyclonal knockout model thus enables the dissection of EPHA1-specific contributions to lymphoblast biology without the confounding effects of clonal variation.
This product is suitable for a range of applications including investigation of ephrin signaling in lymphoma, cell adhesion and migration assays, drug resistance studies, and analysis of GPCR crosstalk. Researchers can employ techniques such as Western blotting for EPHA1 and downstream effectors, flow cytometry, co-immunoprecipitation to assess protein complexes, migration/invasion assays, and drug sensitivity profiling. For further technical details, please contact Ascent Research.
